News

Sunovion Re-Submits Approval Request for APL-130277 to FDA for Treating Parkinson’s Off Periods

Sunovion Pharmaceuticals has re-submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), once again seeking the approval of its below-the-tongue formulation of apomorphine — called APL-130277 — for Parkinson’s off periods. The re-submission is a follow-up to the FDA’s “complete response…

Researchers Identify Gene Networks Underlying Parkinson’s Development

Researchers have found new gene networks associated with the development of Parkinson’s disease, which may help them understand the underlying mechanisms of this neurodegenerative disorder and identify potential new therapeutic targets. The study, “The landscape of multiscale transcriptomic networks and key regulators in Parkinson’s disease,” was published in…